DiaMedica Therapeutics (DMAC) Interest Expenses (2017 - 2026)

DiaMedica Therapeutics' Interest Expenses history runs 10 years deep, the most recent figure standing at $23000.0 for Q1 2026.

• On a quarterly basis, Interest Expenses rose 2200.0% year-over-year to $23000.0 in Q1 2026; TTM through Mar 2026 was $43000.0, a 115.0% increase from a year earlier, with the FY2025 full-year figure at $42.4 million, up 24.07% from the prior year.
• Interest Expenses retreated to $23000.0 in Q1 2026 per DMAC's latest filing, from $26.5 million in the prior quarter.
• Across five years, Interest Expenses topped out at $26.5 million in Q4 2025 and bottomed at $1000.0 in Q1 2022.
• The 5-year median for Interest Expenses is $832000.0 (2022), against an average of $4.6 million.
• Across the five-year window, Interest Expenses slumped 99.98% in 2022 and jumped 11500.0% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $832000.0 in 2022, then changed by 0.0% to $832000.0 in 2023, then soared by 1131.13% to $10.2 million in 2024, then jumped by 158.51% to $26.5 million in 2025, then sank by 99.91% to $23000.0 in 2026.
• Per Business Quant, the three latest DMAC Interest Expenses figures stand at $23000.0 (Q1 2026), $26.5 million (Q4 2025), and $21.2 million (Q3 2025).